Ticagrelor vs Clopidogrel Effect on MFR in CAD Population

Study Overview
=================
Brief Summary
-----------------
Ticagrelor is one of 3 anti-platelet medications used in patients with acute coronary syndrome (ACS) to prevent further clot formation and further ischemic damage to myocardial tissue. Overall benefits of one drug over the other is neutral in this generally unstable population. In pre-clinical trials, ticagrelor showed secondary effects, involving the release of adenosine to heart muscle where the demand for blood was increased due to a stress condition. Blood flow was increased, potentially preventing potential damage. This study will compare ticagrelor, currently only approved for use in ACS patients, against clopidogrel by measuring the myocardial blood flow(MBF) during stress to validate this phenomenon. The effect on blood flow will be measurable by using two specific doses of adenosine as the pharmacologic stress and correlating with measurements of blood flow using positron emission tomography (PET) nuclear imaging. This study hypothesizes that the increase in MBF during intermediate dose adenosine infusion will be greater in ticagrelor treated subjects compared to clopidogrel treated subjects

Official Title
-----------------
ComPArison of the Effect of Ticagrelor Versus Clopidogrel on Myocardial Blood Flow (MBF) and Reserve (MBFR) Measured With Positron Emission TomograpHy (PET) in Patients With Coronary Artery Disease (CAD): The PATH Study

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Drug: Ticagrelor
* Drug: Clopidogrel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old Stable coronary artery disease on stable medical treatment. BMI equal to or less than 30 kg/m2 No clinically significant abnormalities in baseline laboratory work No clinically significant arrhythmias on baseline 12-lead electrocardiogram Female subjects must be post-menopausal, surgically sterilized or have negative urine beta human chorionic gonadotropin pregnancy test at initial screening and maintain effective contraceptive methods throughout the trial and for 7 days following the end of dosing treatment. Exclusion Criteria: Any contraindication against the use of clopidogrel, ticagrelor and/or ASA. Oral anticoagulation therapy. History of intracranial bleeding. Recent or active pathological bleeding, such as peptic ulcer. Moderate or severe hepatic impairment. History or risk of bradycardia. Known second- or third-degree AV block without pacemaker Dyspnea (NYHA III/IV), wheezing asthma or COPD. Coronary artery bypass graft (CABG) surgery within 90 days prior to screening or at any time after consent. Percutaneous coronary intervention (PCI) within 90 days prior to screening or at any time following consent. Acute myocardial infarction or acute coronary syndrome within 60 days prior to screening or at any time following consent. Any scheduled surgery during the trial period, including dental. Concomitant therapy with strong cytochrome CYP 3A inhibitor or inducer. Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox) Known hypersensitivity to the investigational drug or any of its components. Known hypersensitivity to adenosine. Lactose intolerance Breastfeeding or pregnancy. Claustrophobia or inability to lie still in a supine position Unwillingness to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: stable CAD management<br>Experimental: Ticagrelor (BrilintaTM) 90 mg tablet by mouth twice a day | Drug: Ticagrelor<br>* Blinded administration of ticagrelor for 10 days<br>* Other names: BrilintaTM;Drug: Clopidogrel<br>* Blinded administration of clopidogrel and placebo for 10 days<br>|
| Active Comparator: CAD comparison group<br>Active comparator: clopidogrel 75 mg plus placebo tablet by mouth twice a day. | Drug: Ticagrelor<br>* Blinded administration of ticagrelor for 10 days<br>* Other names: BrilintaTM;Drug: Clopidogrel<br>* Blinded administration of clopidogrel and placebo for 10 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences in rest MBF, stress MBF and MBFR between ticagrelor and clopidogrel treated patients as measured by PET | Blinded study drug will be administered for 10 days after which the subject will undergo MPI imaging to measure MBF. The crossover to the other study arm will occur and the study procedure repeated. Actual study drug effect will not be known until the study has completed and the treatment unblinded. | q 2 weeks blood flow measurements | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effect of ticagrelor on rest MBF, stress MBF and MBFR will be compared in the normal versus abnormal segments on a segmental and patient basis in the ticagrelor treated subjects | Blinded study drug will be administered for 10 days after which the subject will undergo MPI imaging to measure rest/stress MBF and myocardial blood flow reserve. The crossover to the other study arm will occur and the study procedure repeated. Actual study drug effecting flow will not be known until the study has completed and the treatment unblinded. | q 2 weeks blood flow measurements | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
myocardial blood flow, myocardial perfusion imaging, myocardial blood flow reserve, positron emission tomography, adenosine, ticagrelor, clopidogrel